Drug
Florbenazine F 18 clinical trials
Also written 18F-DTBZ and 18F-AV-133.
- studies test it
- 11
- open now
- 1
- in phase 3
- 0
- first study started
- 2010
Keep track of what changes. Save the florbenazine F 18 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Other names
Studies by the year they started
11 studies that test it; most in 2010 (3)
| Year | Studies |
|---|---|
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 3 |
| 2015 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 3
- Phase 2
- 8
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 8
Chang Gung Memorial Hospital (6) · Avid Radiopharmaceuticals (3) · Columbia University (1) · Michael J. Fox Foundation for Parkinson's Research (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses florbenazine F 18 is read from its arms, and is right about nine times in ten.
Testing it · 11
- This Protocol is a Sub-study Under the PPMI Program. It is a Longitudinal, Single-center Study to Assess the Performance of [18F]AV-133 Imaging Using High and Standard Resolution PET in Individuals Enrolled With Parkinson's Disease (PD) for up to 12 Months.RecruitingPhase 2Michael J. Fox Foundation for Parkinson's ResearchNCT07830654Written as [18F]AV-133
- Evaluation of 18 F-FP-DTBZ Pancreatic PET Scanning as a Tool to Measure Beta Cell MassCompletedEarly Phase 1Columbia UniversityNCT02236754Written as 18 F-FP-DTBZ
- A Trial of 18F-AV-133 Positron Emission Tomography (PET)TerminatedPhase 1Avid RadiopharmaceuticalsNCT01515384Written as 18F-AV-133
- Investigating the Microstructural and Functional Alterations of Brain in Parkinson's Disease PatientsCompletedPhase 2Chang Gung Memorial HospitalNCT02599753Written as 18-FDTBZ
- Developing a Novel Imaging Biomarker in the Differential Diagnosis of Parkinson's Disease and ParkinsonismCompletedPhase 2Chang Gung Memorial HospitalNCT02059733Written as 18F-DTBZ
- 18F-DTBZ PET and Multi-modal MRI in the Patients With Vascular ParkinsonismCompletedPhase 2Chang Gung Memorial HospitalNCT02195154Written as 18F-DTBZ
- Imaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PETCompletedPhase 2Chang Gung Memorial HospitalNCT02039024Written as 18F- DTBZ
- Quantitative 18F-AV-133 PET Imaging in Subjects With Diabetes and Healthy ControlsCompletedPhase 1Avid RadiopharmaceuticalsNCT01710371Written as 18F-AV-133
- Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 ParkinsonismCompletedPhase 2Chang Gung Memorial HospitalNCT01759888Written as 18F-DTBZ
- 18F-DTBZ for l Diagnosis of Parkinson's Disease and Monitoring the Severity of Disease by VMAT2 PET ImagingCompletedPhase 2Chang Gung Memorial HospitalNCT01283347Written as 18F-DTBZ
- A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)CompletedPhase 1/2Avid RadiopharmaceuticalsNCT01503944Written as 18F-AV-133
Codes
What other systems call florbenazine F 18 · ClinicalTrials.gg INT005629
- MeSH (NLM) C549477florbenazine F 18Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) KM31LBX59HFLORBENAZINE F-18Confirmed FDA, NLM, Wikidata
- Wikidata Q27282331florbenazine f-18Confirmed FDA, NLM, Wikidata
- NCI Thesaurus C171883Florbenazine F-18One source FDA
- DrugBank DB14945One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C549477 | florbenazine F 18 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | KM31LBX59H | FLORBENAZINE F-18 | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27282331 | florbenazine f-18 | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171883 | Florbenazine F-18 | One source FDA |
| DrugBank | DB14945 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.